Leucine

Generic Name: Leucine

Brand Names: Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinimix 2.75/5, Clinimix E 2.75/5, Clinisol 15, Freamine 6.9, Freamine III 10, Hepatamine 8, Nephramine, Olimel, Periolimel, Plenamine, Premasol, Primene, Procalamine 3, Prosol, Travasol 10, Trophamine 10 %

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₃NO_₂

CAS Number: 61-90-5

Unique Ingredient Identifier: GMW67QNF9C

Background: An essential branched-chain amino acid important for hemoglobin formation.

Indication: Indicated to assist in the prevention of the breakdown of muscle proteins that sometimes occur after trauma or severe stress.

Associated Conditions: Hypoalbuminemia

Associated Therapies: Amino acid supplementation

Clinical Trials

Leucine in Midlife Depression

Phase 2

Recruiting

Conditions: Major Depression

Interventions: Drug: L-leucine
Drug: L-lysine

First Posted Date: 2024-08-30

Last Posted Date: 2025-04-24

Lead Sponsor: Emory University

Target Recruit Count: 75

Registration Number: NCT06580145

Locations: 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States

The Effect of Carnitine Supplementation on Cardiac Function and Lipid Profile in Patients With Drug Resistant Epilepsy on Ketogenic Diet

Early Phase 1

Active, not recruiting

Conditions: l Carnitine With Ketogenic Diet

Interventions: Drug: L Carnitine

First Posted Date: 2024-01-10

Last Posted Date: 2024-01-10

Lead Sponsor: Ain Shams University

Target Recruit Count: 52

Registration Number: NCT06198803

Locations: 🇪🇬
Cairo, Cairo, Egypt

Maximal Use Study to Determine the Pharmacokinetics of L-arginine After Exaggerated Oral Use of COL101

Phase 1

Completed

Conditions: Caries,Dental

Interventions: Drug: L Arginine
Drug: Sodium Fluoride

First Posted Date: 2023-12-26

Last Posted Date: 2024-01-02

Lead Sponsor: Colgate Palmolive

Target Recruit Count: 29

Registration Number: NCT06182267

Locations: 🇺🇸
TKL Research, Inc, Fair Lawn, New Jersey, United States

Evaluation of the Impact of L- Carnitine in Intradialytic Hypotension in Pediatric Patients on Regular Hemodialysis

Phase 3

Active, not recruiting

Conditions: Intradialytic Hypotension

Interventions: Drug: L Carnitine

First Posted Date: 2023-06-15

Last Posted Date: 2023-06-15

Lead Sponsor: Ain Shams University

Target Recruit Count: 50

Registration Number: NCT05905692

Locations: 🇪🇬
Radwa Maher El Borolossy, Cairo, Egypt

High-dose L-Carnitine and Diaphragmatic Function Assessed by Ultrasonography in Patients With Respiratory Failure.

Phase 4

Completed

Conditions: Respiratory Failure

Interventions: Drug: L Carnitine ( low dose)
Drug: L-Carnitine ( high dose)

First Posted Date: 2022-04-11

Last Posted Date: 2022-10-17

Lead Sponsor: Ain Shams University

Target Recruit Count: 60

Registration Number: NCT05322447

Locations: 🇪🇬
Faculty of medicine, Cairo, Egypt
🇪🇬
Mona A Ammar, Cairo, Egypt

The Effect of Lidocaine Patch for Postoperative Pain

Phase 4

Completed

Conditions: Acute Pain

Interventions: Drug: Group L

First Posted Date: 2021-02-15

Last Posted Date: 2023-12-26

Lead Sponsor: BON WOOK KOO

Target Recruit Count: 32

Registration Number: NCT04754451

Locations: 🇰🇷
Seoul National Universuty, Bundang Hospital, Seongnam-si, Gyonggido, Korea, Republic of

L Brevis for Traumatic Oral Lesions in Orthodontic Patients

Phase 2

Completed

Conditions: Oral Mucositis
Bacterium; Agent
Orthodontic Appliance Complication

Interventions: Drug: L brevis
Drug: Placebo

First Posted Date: 2020-05-21

Last Posted Date: 2020-05-21

Lead Sponsor: Universidade de Passo Fundo

Target Recruit Count: 20

Registration Number: NCT04398511

Locations: 🇧🇷
Post-Graduate Program in Dentistry, Passo Fundo, Brazil

Treatment of Adults With Generalized Anxiety Disorder Using Glutamine

Phase 2

Terminated

Conditions: Generalized Anxiety Disorder

Interventions: Drug: L Glutamine
Drug: Placebos

First Posted Date: 2020-02-18

Last Posted Date: 2021-02-11

Lead Sponsor: Hospital Universitario Dr. Jose E. Gonzalez

Target Recruit Count: 38

Registration Number: NCT04274114

Locations: 🇲🇽
Hospital Universitario Dr. Jose E. Gonzalez, Monterrey, Nuevo León, Mexico

Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Phase 2

Terminated

Conditions: Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia

Interventions: Drug: Isatuximab
Drug: Dexamethasone or equivalent
Drug: Fludarabine
Drug: Cytarabine
Drug: Liposomal daunorubicin
Drug: Daunorubicin (nonliposomal)
Drug: Idarubicin
Drug: Filgrastim or equivalent
Drug: Mitoxantrone
Drug: Doxorubicin
Drug: Vincristine
Drug: Pegaspargase (PEG) Asparaginase
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Methotrexate
Drug: L - Asparginase
Drug: Hydroxyurea
Drug: L - Asparaginase (Erwinase)

First Posted Date: 2019-03-04

Last Posted Date: 2024-05-16

Lead Sponsor: Sanofi

Target Recruit Count: 67

Registration Number: NCT03860844

Locations: 🇺🇸
Children's Medical Center of Dallas-Site Number:8400002, Dallas, Texas, United States
🇲🇽
Investigational Site Number :4840001, Monterrey, Nuevo León, Mexico
🇧🇷
Investigational Site Number :0760007, Porto Alegre, Rio Grande Do Sul, Brazil

and more 38 locations

The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity

Phase 2

Completed

Conditions: Obesity

Interventions: Drug: Placebo
Drug: Leu Sil 1.0mg
Drug: Leu Sil 4.0mg
Drug: Leu Met Sil 1.0mg
Drug: Leu Met Sil 4.0mg

First Posted Date: 2017-12-06

Last Posted Date: 2019-08-21

Lead Sponsor: NuSirt Biopharma

Target Recruit Count: 267

Registration Number: NCT03364335

Locations: 🇺🇸
Northern California Research, Sacramento, California, United States
🇺🇸
ACR, Jordan, Utah, United States
🇺🇸
Premier, Clarksville, Tennessee, United States

and more 7 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy